Cetuximab and panitumumab have an effective therapeutic response in a subset ofRASWild-Type (WT) metastatic colorectal cancers (mCRCs). Despite molecular-driven selection, all patients do not respond to epidermal growth factor receptor (EGFR) inhibitors and the onset of secondary resistance limits their clinical benefit.
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
Napolitano, Stefania;Martini, Giulia;Martinelli, ErikaData Curation
;Morgillo, FlorianaMethodology
;Ciardiello, FortunatoMethodology
;Troiani, Teresa
2017
Abstract
Cetuximab and panitumumab have an effective therapeutic response in a subset ofRASWild-Type (WT) metastatic colorectal cancers (mCRCs). Despite molecular-driven selection, all patients do not respond to epidermal growth factor receptor (EGFR) inhibitors and the onset of secondary resistance limits their clinical benefit.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
